$FTRE

Mcconnell Jill G. sold $75K of FTRE

Mcconnell Jill G. (Chief Financial Officer) sold 4,866 shares of Fortrea Holdings Inc. (FTRE) at $15.49 on 2026-06-02.

Original reporting
SEC EDGAR · Mcconnell Jill G.
Published Jun 3, 2026, 8:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FTRE
Neutral
low confidence
Mentioned
$FTRE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

Treat as a sentiment/positioning datapoint rather than a fundamental driver; monitor for follow-on filings (additional sales/buys) and any concurrent company news.

02

Market read

A disclosed CFO sale may slightly weigh on short-term sentiment, but it is unlikely to move the stock materially without corroborating fundamental catalysts.

03

What to watch

The article does not state motivations, whether proceeds were for taxes, or whether other insiders/large holders are buying; absence of a 10b5-1 plan detail may increase noise rather than signal.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed June 3 (transaction dated June 2)

Background

The article is an SEC insider transaction disclosure (Form 4) for Fortrea Holdings’ CFO.

Company-level read

Ticker impact

$FTRENeutralLow confidence
Context

Fortrea CFO Jill McConnell sold 4,866 shares in an open-market transaction disclosed via SEC Form 4 on June 2.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional insider activity or fundamentals.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying company-specific operational or financial news; 10b5-1 plan is explicitly noted as not pre-arranged, but the sale size is not described as material to fundamentals.

Market effects

Minimal; this is company-specific insider activity without sector-wide implications.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine for diversification/taxes and do not necessarily reflect negative expectations.

Key entities

  • Fortrea Holdings Inc.

    Subject of the SEC Form 4 insider transaction disclosure.

  • Jill G. McConnell

    Fortrea CFO who sold shares via open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FTREMed

Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Holdings (FTRE) shares rose 2.8% after acquiring Worldwide Clinical Trials' Early Phase Services division, expanding its clinical research capabilities. The acquisition includes facilities in Texas. Fortrea's stock is volatile, with a 52-week high of $20.70. Q3 revenue was $701.3M, beating estimates, but earnings missed. Full-year revenue guidance was raised to $2.73B.

$FTREHigh

Fortrea To Acquire Early Phase Services From Worldwide Clinical Trials; Stock Up

Fortrea Holdings (FTRE) agreed to buy the Early Phase Services division of Worldwide Clinical Trials, including labs and clinical units in Texas. The deal expands Fortrea's early development network, adding bioanalytical and clinical pharmacology capabilities. FTRE shares rose 5.98% to $18.78. According to the company, the acquisition supports growth and increases long-term shareholder value.

$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.